2025-2034 Breast Cancer Liquid Biopsy Market Evolution: Disruptions, Innovations, and Untapped Opportunities

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Breast Cancer Liquid Biopsy Market Through 2025?
In recent times, the market size of the breast cancer liquid biopsy has experienced swift expansion. Its growth is projected to rise from $0.78 billion in 2024 to $0.89 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.2%. Factors such as progress in next-generation sequencing (ngs), a rising incidence of breast cancer, an amplified demand for non-invasive diagnostic techniques, an increase in the acceptance of personalized medicine, and expanded financing for cancer research, significantly contribute to the market's growth in the historical period.

What's the Projected Size of the Global Breast Cancer Liquid Biopsy Market by 2029?
The size of the market for breast cancer liquid biopsies is poised for considerable growth over the coming years, set to reach a $1.53 billion value by 2029, and a compound annual growth rate (CAGR) of 14.5%. Factors contributing to this predicted upturn include enhanced technology within liquid biopsy processes, increasing use of the method for early cancer detection, a growing demand for real-time observation of cancer progression, wider application in precision oncology, as well as increased investment in related research and development. Additionally, key emerging trends for the forecasted period are artificial intelligence application in liquid biopsy results analysis, single-cell sequencing advancements, multi-omics liquid biopsy platform development, improved sensitivity and specificity in liquid biopsies, and increased use of digital pcr for ultra-precise identification of mutations.

View the full report here:
https://www.thebusinessresearchcompany.com/report/breast-cancer-liquid-biopsy-global-market-report

Top Growth Drivers in the Breast Cancer Liquid Biopsy Industry: What's Accelerating the Market?
The uptick in instances of breast cancer is projected to stimulate the expansion of the breast cancer liquid biopsy market. Specifically, this type of cancer forms in the cells of the breast, generally in the lobules (the glands that produce milk) or in the ducts (the channels that transport milk to the nipple). An increase in breast cancer cases is influenced by factors such as genetic factors, hormonal imbalances, an aging demographic, lifestyle changes, obesity, alcohol intake, insufficient physical activity, exposure to radiation, and environmental pollutants. A liquid biopsy for breast cancer is employed in patient care to identify circulating DNA from a tumor (ctDNA) or circulating tumor cells (CTCs) in the blood, enabling real-time disease monitoring. The biopsy assists in evaluating the patient's response to treatment, identifies resistance to therapy, and uncovers genetic mutations for targeted therapies. For example, the American Cancer Society, a US non-profit focused on research, advocacy, and patient support for cancer, estimates that the number of new breast cancer cases will increase to 319,750 in 2025, an increase from 313,510 in 2024. Consequently, the rise in breast cancer occurrences is propelling the growth of the breast cancer liquid biopsy market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21119&type=smp

What Are the Key Trends Driving Breast Cancer Liquid Biopsy Market Growth?
In the breast cancer liquid biopsy market, leading corporations are concentrating on the development of innovative products such as companion diagnostics. These diagnostics are designed to identify specific patients who could benefit from precise therapies, using liquid biopsy technologies. They identify markers like genetic mutations, circulating tumor DNA (ctDNA), or protein expressions that show responsiveness to specific treatments. For instance, Guardant Health Inc, a biotech firm based in the US, earned FDA approval in January 2023 for its Guardant360 CDx liquid biopsy test. This test is a companion diagnostic for ORSERDU (elacestrant), a medication by the Menarini Group, designed to treat patients of advanced or metastatic breast cancer with ESR1 mutations. With this FDA approval, oncologists can now use the test to perform comprehensive genomic profiling and to identify patients who are suitable for the targeted therapy. This stands as Guardant Health's inaugural FDA approval for breast cancer, further solidifying its position in precision oncology.

What Are the Main Segments in the Breast Cancer Liquid Biopsy Market?
The breast cancer liquid biopsy market covered in this report is segmented -

1) By Product: Consumables, Kits
2) By Biomarkers: Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), Circulating Tumor RNA (ctRNA), Circulating Tumor Cells (CTCs), Cell-free RNA (cfRNA), Other Biomarkers
3) By Application: Early Detection Or Screening, Diagnosis, Other Applications
4) By End Users: Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, Pathology Laboratories

Subsegments:
1) By Consumables: Reagents, Polymerase Chain Reaction (PCR) Assays, Sequencing Panels, Sample Collection Tubes
2) By Kits: DNA-based Liquid Biopsy Kits, RNA-based Liquid Biopsy Kits, Multi-marker Liquid Biopsy Kits

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21119&type=smp

Which Top Companies are Driving Growth in the Breast Cancer Liquid Biopsy Market?
Major companies operating in the breast cancer liquid biopsy market are Johnson & Johnson Private Limited, Roche Diagnostics, Merck KGaA, Thermo Fisher Scientific, Siemens Healthineers, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Qiagen N.V., Myriad Genetics Inc., NeoGenomics Laboratories, Guardant Health Inc., Twist Bioscience, Foundation Medicine Inc., Biodesix Inc., Menarini Silicon Biosystems, Datar Cancer Genetics, Abcam plc, OncoDNA SA, Genomic Health Inc., RainDance Technologies, Biocept Inc., Fluxion Biosciences Inc., Angle plc

Which Regions Will Dominate the Breast Cancer Liquid Biopsy Market Through 2029?
North America was the largest region in the breast cancer liquid biopsy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer liquid biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21119

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

"

#Reach Out to Us#

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com

Follow Us On:
• LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.